Efficiency of lyticase (bacterial enzyme) in experimental candidal vaginitis in mice.

Lyticase (a bacterial enzyme) was tested as a new antimycotic drug. Of all objects studied, Cellulomonas cellulans AC-870 strain proved to be most productive for this enzyme. A technology for lyticase isolation and purification was proposed. An experimental model of recurrent vaginal candidiasis was created. The model includes combined antibiotic and estradiol therapy. Antimycotic effect of lyticase on the model of recurrent vaginal candidiasis in mice was demonstrated.

Study of antimycotic activity of lyticase.

Laboratory studies of lyticase (enzymatic drug) as an antimycotic agent were carried out. The enzyme reduced optical density of Candida albicans test culture, inhibited adhesion of yeast-like fungi on vaginal epitheliocytes, stimulated the formation of germinative tubes, and made Candida albicans more available for phagocytosis.

The influence of carbohydrases on the growth of fungal pathogens in vitro and in vivo.

Mixtures of mycolytic enzymes from various sources release protoplasts from living fungal tissue under suitable conditions. Such enzyme mixtures obtained from Coprinus comatus (mycolase I), Physarum polycephalum (mycolase II) and Lycoperdon pyriforme (mycolase III) are of low toxicity in mammals when given parenterally and are able to cure experimental systemic fungal infections in mice when administered alone or in conjunction with normally ineffective levels of conventional antimycotic drugs such as amphotericin B. The effect is believed to be due to enzymic degradation of the fungal cell wall either killing the fungus directly or enhancing activity of existing antifungal agents by increasing access to the cell interior.